Ventricular assist devices (VADs) are mechanical pumps that are used to support heart function and blood flow in people who have weakened hearts. They help pump blood from the lower chambers of the heart (ventricles) to the rest of the body. VADs are typically used in people awaiting a heart transplant or as a long-term treatment known as destination therapy for people who are not candidates for a heart transplant. This article explores the different types of VADs, how they work, and their benefits and risks. It also discusses the market outlook for VADs given their promising role in helping heart failure patients.
Types of VADs
There are two main types of VADs – left ventricular assist devices (LVADs) and right ventricular assist devices (RVADs). LVADs are more commonly used as they help pump blood from the left ventricle, which is the main pumping chamber of the heart, to the rest of the body. RVADs help pump blood from the right ventricle to the lungs. Some key LVAD devices on the market include the HeartMate 3 and HeartWare HVAD system.
How VADs Work
VADs work by artificially taking over some of the heart’s pumping function. LVADs are connected via tubes (grafts) from the left ventricle to the aorta. A battery-operated mechanical pump housed in the abdomen pumps oxygen-rich blood from the heart into the body’s major arteries. The heart still provides some pumping function as well. RVADs operate in a similar way, circulating blood from the right ventricle to the lungs. Control panels and controllers monitor device function and send information to clinicians. This helps ensure appropriate blood flow and reduces strenuous work for the native heart.
Ventricular Assist Devices Market by Coherent Market Insights discusses Benefits of VAD Therapy as followed
The main benefit of VAD therapy is that it can improve symptoms, exercise capacity, and quality of life for those suffering from advanced heart failure. By taking over some of the pumping work of the ventricles, it reduces stress on the heart and increases blood flow throughout the body. This treats symptoms like extreme fatigue and shortness of breath. It also allows heart failure patients to participate in activities that were previously difficult.
Some key benefits include:
- Bridging patients to heart transplant or recovery of native heart function
- Allows for recovery time on the transplant waitlist
- Long-term “destination” option for those not eligible for transplant
- Over 90% survival at 1 year with VAD as bridge to transplant
- May improve survival in those not transplant candidates
Risks of VAD Therapy
While life-saving, VAD therapy is not without risks. Some potential complications include bleeding, blood clots, device-related infections, and device malfunctions. There are also ongoing risks associated with battery packs, connections, and controllers. Lifestyle adjustments are also needed which can impact quality of life. Careful management by specialized teams is important. However, risks of long-term management have decreased in recent years due to improvements in device design and surgical techniques.
Market Outlook
The ventricular assist device market is expected to experience robust growth globally in the coming years, driven by aging populations, rising heart failure prevalence, and continued technological advances expanding treatment options for patients. The growing heart failure burden globally will fuel market demand as VADs allow patients increased survival and quality of life where few other options exist. The United States currently dominates the VAD market due to higher adoption rates and favorable reimbursement coverage compared to most other regions. However, Asia Pacific and other emerging markets are anticipated to offer attractive growth opportunities as access to VAD therapy expands in line with rising economic ability to address heart disease. For more details on current and projected market opportunities within this sector, including emerging trends and factors influencing industry performance, please refer to the report published on the Coherent Market Insights website.
In conclusion, VAD therapy plays an important role in saving and improving lives for heart failure patients who are waiting for transplants or not deemed eligible for them. Newer devices aim to reduce complications while maintaining strong clinical efficacy. Improved device technology, expanded facilities globally, and a growing understanding of VAD therapy will serve to further help many suffering from advanced heart disease in need of this life-giving support. With the rising human and economic toll of heart failure worldwide, ventricular assist devices provide welcome options that will see continued development and adoption.
